Skip to main content
. Author manuscript; available in PMC: 2009 Jun 8.
Published in final edited form as: Oncology (Williston Park). 2006 Aug;20(9):1029–1048.

Table 1.

Treatment Guidelines for Patients With Breast Cancer on Aromatase Inhibitor Therapy

DXAT Score Diagnosis Recommendations
>−1 Normal Annual DXA screening Ca++ intake ≥1,200 mg/d Vitamin D intake 400 to 800 IU/d
−1 to −2.5 Osteopenia Consider bisphosphonate therapy if other risk factors present Annual DXA screening Ca++ intake ≥1,200 mg/d Vitamin D intake 400 to 800 IU/d
≤ −2.5b Osteoporosis Initiate bisphosphonate therapy Annual DXA screening Ca++ intake ≥1,200 mg/d Vitamin D Intake 400 to 800 IU/d
≤ −2.5 (with ≥1 fragility fracture) Severe osteoporosis Initiate bisphosphonate therapy Annual DXA screening Ca++ Intake ≥1,200 mg/d Vitamin D Intake 400 to 800 IU/d
a

Information from References 1,25, and 56.

b

National Osteoporosis Foundation recommendation is to initiate bisphosphonate therapy at a T score of < −2 rather than −2.5.

DXA = dual-energy x-ray absorptiometry.